MedTrace Logo

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

NCT02178098 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2023-04-04

Study results available
· View outcomes & findings →

Summary

This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in participants with hypercholesterolemia and hypertension.

Conditions

Interventions

DRUG

ETC-1002

ETC-1002 capsules taken once daily

DRUG

Placebo

Placebo capsules taken once daily

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • Esperion Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Medpace Medical Monitor · Medpace, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-16
Primary Completion
2015-05-22
Completion
2015-05-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02178098 on ClinicalTrials.gov